BRCA1 dysfunction in sporadic basal-like breast cancer
By N. Turner, J. S. Reis-Filho, A. Russell, R. Springall, K. Ryder, Dawn Steele, K. Savage, C. Gillett, F. Schmitt, Alan Ashworth and 1 more. Oncogene, 2007
618 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/eaccbbe92f27d95818674f505aae5be698b4e424
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
- J. Reis-Filho
- William T. Barry
- A. Richardson
- Bryan T. J. Hennessy
- Gordon B. Mills
- Zoltan Szallasi
- Andrew Tutt
Citations in the corpus
- Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. (2011, neutral): “00 (referent) ER(1)/PR(2) 25 256 (10) 1006 (40) 830 (33) 313 (12) 134 (5) 1.”
- Triple-negative breast cancer--current status and future directions. (2009, background): “For instance, up to 15%–45% of BLBCs have been shown to express ER [9, 16] and 14% of BLBCs to express HER-2 [16], indicating that not all BLBCs regardless of classification method are TN. Conversely, while 16%–44% of TN cases are negative for all basal markers (CK5/6, CK14, EGFR) [17, 18], 7.3% of ”
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016, background): “Sporadic (BRCA1 and BRCA2 germline wild type) TNBCs share many characteristics with BRCA1 mutation-associated cancers, including a basal-like gene expression profile, frequent p53 mutations, and a high burden of genomic aberrations such as loss of heterozygosity (1-7).”
- Triple negative tumours: a critical review (2007, background): “We therefore investigated alternative epigenetic mechanisms of BRCA1 pathway inactivation and found that sporadic invasive ductal carcinomas with a basal-like phenotype expressed ID4, a negative regulator of BRCA1,(93,94) at significantly higher levels than grade-matched controls.(53) This mechanism”